PeRampanel fOr Status ePilEpticus pRophylaxis Post-cardiac Arrest
University of California, San Francisco
Summary
Brain injury is the main cause of death and disability for patients surviving cardiac arrest resuscitation and seizures are diagnosed in up to a third of these patients. The investigators are proposing a pilot randomized placebo-controlled clinical trial to evaluate the safety and feasibility of perampanel use for post-cardiac arrest status epilepticus (PCARSE) prevention after cardiac arrest.
Description
More than 500,000 Americans have a cardiac arrest every year and 100,000 survive to hospital admission. Brain injury is the main cause of death and disability for patients surviving cardiac arrest resuscitation and seizures are diagnosed in up to a third of these patients. Seizures with or without muscle jerks, i.e. myoclonic seizures, are the most common seizure type after a cardiac arrest. Despite being common, seizures are usually refractory to treatment (post-cardiac arrest refractory status epilepticus) and the vast majority of patients with this diagnosis die. We are proposing a pilot ra…
Eligibility
- Age range
- 18+ years
- Sex
- All
- Healthy volunteers
- No
Inclusion Criteria: * Age ≥18 years old * Non-traumatic, out-of-hospital cardiac arrest * Comatose on admission - defined as not following commands * Return of spontaneous circulation (ROSC) within less than 45 minutes from the time of cardiac arrest (defined as the time of 911 or EMS (emergency medical services) witnessed arrest) * Admission to the intensive care unit at Zuckerberg San Francisco General Hospital Exclusion Criteria: * Acute cerebral hemorrhage or infarction * Pregnancy * Prisoner * Severe kidney function impairment with creatinine clearance inferior to 30 ml/min * Severe li…
Interventions
- DrugPerampanel
Perampanel is a non-competitive AMPA glutamate receptor antagonist.
- DrugPlacebo
Placebo
Location
- Zuckerberg San Francisco General HospitalSan Francisco, California